A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC)

详细信息    查看全文

• 作者：Hidehito Horinouchi (1)
  Noboru Yamamoto (1)
  Hiroshi Nokihara (1)
  Takeshi Horai (2)
  Makoto Nishio (2)
  Fumiyoshi Ohyanagi (2)
  Atsushi Horiike (2)
  Kazuhiko Nakagawa (3)
  Masaaki Terashima (3)
  Takafumi Okabe (3)
  Hiroyasu Kaneda (3)
  Mark D. McKee (4)
  Dawn M. Carlson (4)
  Hao Xiong (4)
  Tomohide Tamura (1)
  
• 关键词：Angiogenesis ; Linifanib (ABT ; 869) ; NSCLC ; PDGFR ; VEGFR
• 刊名：Cancer Chemotherapy and Pharmacology
• 出版年：2014
• 出版时间：July 2014
• 年：2014
• 卷：74
• 期：1
• 页码：37-43
• 全文大小：399 KB
• 参考文献：1. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346(2):92-8 CrossRef
  2. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Janne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ (2010) Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363(18):1693-703 CrossRef
  3. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Janne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT (2012) Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 13(10):1011-019 CrossRef
  4. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I, Fujita Y, Okinaga S, Hirano H, Yoshimori K, Harada T, Ogura T, Ando M, Miyazawa H, Tanaka T, Saijo Y, Hagiwara K, Morita S, Nukiwa T (2010) Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 362(25):2380-388 CrossRef
  5. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121-28 CrossRef
  6. Herbst RS, Onn A, Sandler A (2005) Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 23(14):3243-256 CrossRef
  7. Herbst RS, Heymach JV, Lippman SM (2008) Lung cancer. N Engl J Med 359(13):1367-380 CrossRef
  8. O’Byrne KJ, Koukourakis MI, Giatromanolaki A, Cox G, Turley H, Steward WP, Gatter K, Harris AL (2000) Vascular endothelial growth factor, platelet-derived endothelial cell growth factor and angiogenesis in non-small-cell lung cancer. Br J Cancer 82(8):1427-432. doi:10.1054/bjoc.1999.1129 CrossRef
  9. Giaccone G (2007) The potential of antiangiogenic therapy in non-small cell lung cancer. Clin Cancer Res 13(7):1961-970 CrossRef
  10. Sandler A, Gray R, Perry MC, Brahmer J, Schiller JH, Dowlati A, Lilenbaum R, Johnson DH (2006) Paclitaxel–carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 355(24):2542-550 CrossRef
  11. Zhou J, Goh B-C, Albert D, Chen C-S (2009) ABT-869, a promising multi-targeted tyrosine kinase inhibitor: from bench to bedside. J Hematol Oncol 2:33 CrossRef
  12. Albert DH, Tapang P, Magoc TJ, Pease LJ, Reuter DR, Wei RQ, Li J, Guo J, Bousquet PF, Ghoreishi-Haack NS, Wang B, Bukofzer GT, Wang YC, Stavropoulos JA, Hartandi K, Niquette AL, Soni N, Johnson EF, McCall JO, Bouska JJ, Luo Y, Donawho CK, Dai Y, Marcotte PA, Glaser KB, Michaelides MR, Davidsen SK (2006) Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor. Mol Cancer Ther 5(4):995-006 CrossRef
  13. Albert DH, Reuter D, Ellis PA, Bukofzer G, Donawho CK, McKee MD, Ricker JL, Carlson DM, Davidsen SK (2011) Efficacy of linifanib in preclinical models of NSCLC with wild-type and mutated KRAS. Proc World Conf Lung Cancer 2011:Abstract M011.013
  14. Wong CI, Koh TS, Soo R, Hartono S, Thng CH, McKeegan E, Yong WP, Chen CS, Lee SC, Wong J, Lim R, Sukri N, Lim SE, Ong AB, Steinberg J, Gupta N, Pradhan R, Humerickhouse R, Goh BC (2009) Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with refractory solid malignancies. J Clin Oncol 27(28):4718-726 CrossRef
  15. Liu L, Wu C, Wang Y, Zhong R, Duan S, Wei S, Lin S, Zhang X, Tan W, Yu D, Nie S, Miao X, Lin D (2011) Combined effect of genetic polymorphisms in P53, P73, and MDM2 on non-small cell lung cancer survival. J Thorac Oncol 6(11):1793-800. doi:10.1097/JTO.0b013e3182272273 CrossRef
  16. Asahina H, Tamura Y, Nokihara H, Yamamoto N, Seki Y, Shibata T, Goto Y, Tanioka M, Yamada Y, Coates A, Chiu YL, Li X, Pradhan R, Ansell PJ, McKeegan EM, McKee MD, Carlson DM, Tamura T (2012) An open-label, phase 1 study evaluating safety, tolerability, and pharmacokinetics of linifanib (ABT-869) in Japanese patients with solid tumors. Cancer Chemother Pharmacol 69(6):1477-486 CrossRef
  17. Ramalingam S, Shtivelband M, Soo R, Barrios CH, Makhson A, Segalla J, Pitman K, Kolman P, Rodrigues J, Srkalovic G, Belani C, Axelrod R, Owonikoko T, Qian J, McKee M, Ricker J, Carlson DM, Gorbunova V (2012) Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced squamous NSCLC. J Clin Oncol 30(suppl):abstr 7512
  18. Gupta N, Palaparthy R, Awni W, Carlson D, Pradhan R (2009) Carboplatin/paclitaxel in combination with linifanib (ABT-869) versus carboplatin/paclitaxel alone in patients with advanced or metastatic non-small cell lung cancer (NSCLC) as first-line treatment. J Thorac Oncol 4(9, S1):S669
  
• 作者单位：Hidehito Horinouchi (1)
  Noboru Yamamoto (1)
  Hiroshi Nokihara (1)
  Takeshi Horai (2)
  Makoto Nishio (2)
  Fumiyoshi Ohyanagi (2)
  Atsushi Horiike (2)
  Kazuhiko Nakagawa (3)
  Masaaki Terashima (3)
  Takafumi Okabe (3)
  Hiroyasu Kaneda (3)
  Mark D. McKee (4)
  Dawn M. Carlson (4)
  Hao Xiong (4)
  Tomohide Tamura (1)
  
  1. Department of Thoracic Oncology, National Cancer Center Hospital, Tsukiji 5-1-1, Chuo-ku, Tokyo, Japan
  2. Thoracic Medical Oncology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan
  3. Department of Medical Oncology, Faculty of Medicine, Kinki University, Osaka, Japan
  4. AbbVie, North Chicago, IL, USA
  
• ISSN：1432-0843

文摘

Introduction Linifanib is a potent, orally active, and selective inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptor kinase activities with clinical efficacy in non-small cell lung cancer (NSCLC). This phase 1 dose-escalation study evaluated the pharmacokinetics, safety, and efficacy of linifanib in combination with carboplatin/paclitaxel in Japanese patients with advanced NSCLC. Methods Carboplatin (AUC?=?6?mg/mL/min) and paclitaxel (200?mg/m2) were administered on day 1 of each 21-day cycle up to a maximum of six cycles. Oral linifanib (7.5?mg) was given to six patients once daily throughout all cycles and escalated to 12.5?mg/day in a second cohort of six patients. Results Twelve patients received at least one dose of linifanib. The most common adverse events were hematologic and consistent with expected toxicities with carboplatin/paclitaxel. With 12.5?mg linifanib, grade 3/4 neutropenia, leukopenia, and thrombocytopenia occurred in 100, 83, and 83?% of patients, respectively. Dose-limiting grade 4 thrombocytopenia occurred in one patient at each dose level. Linifanib pharmacokinetics was similar to that in non-Japanese patients. At 12.5?mg, linifanib C max was 0.32 μg/mL and AUC24 was 4.29?μg?h/mL. Linifanib C max occurred at 2-?h with both doses and when given alone or in combination with carboplatin/paclitaxel. Exposure to linifanib appeared to be increased by carboplatin/paclitaxel, and exposure to paclitaxel appeared to be increased by linifanib. Partial responses were observed in nine patients. Conclusions Linifanib added to carboplatin/paclitaxel is well tolerated in Japanese patients with advanced/metastatic NSCLC. The recommended dose of linifanib with carboplatin/paclitaxel is 12.5?mg, same as for US patients.